Parkinson's disease (Q29616302)

Europe PubMed Central

title

Parkinson's disease (English)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19524782

30 April 2017

1 reference

1

Lees AJ

1 reference

30 April 2017

Hardy J

2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19524782

30 April 2017

Revesz T

series ordinal

3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19524782

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19524782

30 April 2017

language of work or name

1 reference

30 April 2017

publication date

13 June 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19524782

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19524782

30 April 2017

volume

373

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19524782

30 April 2017

issue

9680

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19524782

30 April 2017

page(s)

2055-66

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19524782

A new look at James Parkinson's Essay on the Shaking Palsy

30 April 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Prevalence of Parkinson's disease in the elderly: The Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Systematic review of incidence studies of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Did parkinsonism occur before 1817?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Screening for undiagnosed parkinsonism among older people in general practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Smoking and Parkinson's disease: systematic review of prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Cigarette smoking and the incidence of Parkinson's disease in two prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Caffeine, postmenopausal estrogen, and risk of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Nicotinic receptors and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Update in the epidemiology of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Brain monoamine oxidase A inhibition in cigarette smokers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Smoking and Parkinson's disease in twins.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Epidemiologic studies of environmental exposures in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Recreational physical activity and risk of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Epidemiology of Parkinson's disease and akinetic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

alpha-Synuclein locus triplication causes Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

-Synuclein gene duplications in sporadic Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Evidence for mitochondrial dysfunction in Parkinson's disease--a critical appraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Ubiquitin-proteasome system and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Parkin is recruited selectively to impaired mitochondria and promotes their autophagy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Parkinsonism among Gaucher disease carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Neuropathology provides clues to the pathophysiology of Gaucher disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Olfactory Testing as an Aid in the Diagnosis of Parkinson's Disease: Development of Optimal Discrimination Criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Life-threatening parkinsonism induced by kava-kava

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

"Rational hope" in the early treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Movement disorders secondary to adulterated medication

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Patterns of levodopa response in Parkinson's disease: a clinico-pathological study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

The relationship of Parkinson disease with aging

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Long duration asymmetric postural tremor in the development of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Unclassifiable parkinsonism in two European tertiary referral centres for movement disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Olfactory testing in parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

[123I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

How to diagnose multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Clinical outcomes of progressive supranuclear palsy and multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Role of DAT-SPECT in the diagnostic work up of parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Olfaction and Parkinson's syndromes: its role in differential diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

The progression of pathology in longitudinally followed patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Cognitive status correlates with neuropathologic stage in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Dementia with Lewy bodies and Parkinson's disease with dementia: are they different?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Lewy body cortical involvement may not always predict dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Striatal beta-amyloid deposition in Parkinson disease with dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Differences in neuropathologic characteristics across the Lewy body dementia spectrum

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Incidental Lewy body disease and preclinical Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Staging of brain pathology related to sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Controversies over the staging of alpha-synuclein pathology in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: 'permissive templating' as a general mechanism underlying neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Levodopa and the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

DATATOP: A decade of neuroprotective inquiry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Treatment interventions for Parkinson's disease: an evidence based assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

New practice parameters in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

The placebo effect in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Dystonia in Parkinson's disease: clinical and pharmacological features

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Subcutaneous apomorphine in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

The effects of oral protein on the absorption of intraduodenal levodopa and motor performance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Deep brain stimulation for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

A randomized trial of deep-brain stimulation for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Rivastigmine for dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Evidence-based analysis of physical therapy in Parkinson's disease with recommendations for practice and research

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Factors affecting the clinical outcome after neural transplantation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Transplantation in Parkinson's disease: The future looks bright

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Transplantation of embryonic dopamine neurons for severe Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

The search for a curative cell therapy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Results from a phase I safety trial of hAADC gene therapy for Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

Deep brain stimulation for parkinsonian gait disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960492-X

7 January 2021

10.1016/S0140-6736(09)60492-X

Identifiers

DOI

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19524782

30 April 2017

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

526555

OpenCitations bibliographic resource ID

526555

1 reference